Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 3116Neoplasms 2459Carcinoma, Non-Small-Cell Lung 1858Prostatic Neoplasms 1623Colorectal Neoplasms 1401Lung Neoplasms 1293Multiple Myeloma 930Neoplasm Metastasis 919Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 853Ovarian Neoplasms 800Melanoma 782Carcinoma, Hepatocellular 733Stomach Neoplasms 647Squamous Cell Carcinoma of Head and Neck 635Recurrence 635Brain Neoplasms 624Head and Neck Neoplasms 598Glioblastoma 558Lymphoma 549Uterine Cervical Neoplasms 535Triple Negative Breast Neoplasms 511Precursor Cell Lymphoblastic Leukemia-Lymphoma 509Carcinoma, Renal Cell 501Hematologic Neoplasms 464Urinary Bladder Neoplasms 460Endometrial Neoplasms 457Colonic Neoplasms 445Sarcoma 433Lymphoma, Non-Hodgkin 432

Interventions

glofitamab 1Positron Emission Tomography Computed Tomography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Aggression × 1 year × Clear all
NCT02633111 2025-11-04

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Memorial Sloan Kettering Cancer Center

Active not recruiting
501 enrolled
Lymphoid

Aggression, Lymphoma, B-Cell

NCT06534437 2025-09-29

JASPIS-01

Ryvu Therapeutics SA

Phase 2 Recruiting
178 enrolled
Lymphoid

Aggression, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡